New User:

Forgot your password?

Stock Market & Financial Investment News

News For ARNA;VVUS;OREX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 5, 2015
16:04 EDTVVUSVIVUS 'actively pursuing' Latin America partnership for avanafil
"VIVUS is actively pursuing a commercial partnership for avanafil in Latin America, and the company plans to make an announcement as soon as an alliance is secured. VIVUS is encouraged with the plans being executed by its Stendra and Spedra commercialization partners to integrate the 15-minute onset of action data into their promotional campaigns. In parallel, the company has begun examining pulmonary arterial hypertension as a potential additional indication for avanafil, both alone and in combination with another agent," said the company.
16:02 EDTVVUSVIVUS reports Q1 EPS (15c), consensus (22c)
Reports Q1 revenue $32.17M, consensus $21.76M. Reports 136,000 Qsymia prescriptions dispensed.
April 30, 2015
14:30 EDTVVUSAdrianus van Herk reports 5.0% passive stake in VIVUS
Subscribe for More Information
April 29, 2015
08:22 EDTARNAArena Pharmaceuticals' pain treatment candidate shows positive Phase 1 results
Arena Pharmaceuticals announced favorable results from a Phase 1 single-ascending dose clinical trial of APD371, a highly selective and potent agonist of the cannabinoid 2 receptor currently in development for the treatment of pain and potentially fibrotic diseases. The Phase 1 clinical trial showed that APD371 was well tolerated at drug levels greatly exceeding those anticipated as needed for activating the CB2 receptor.
April 28, 2015
07:01 EDTVVUSVIVUS announces discount program through Sam's Club for Qsymia
Subscribe for More Information
April 22, 2015
07:37 EDTOREXOrexigen and Takeda receive Paragraph IV certification notice
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use